Home » Regional Blog & News » CAR T-cell study offers promising outpatient therapy for B-cell lymphoma
CAR T-cell study offers promising outpatient therapy for B-cell lymphoma
August 27, 2019 Earle A. Chiles Research Institute
Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new Phase II clinical trial at Providence Cancer Institute:
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
JCAR017 is an investigational CAR T-cell therapy in which a patient's own T cells are engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen – a protein expressed on the surfaces of normal and malignant B cells. Like other T cells, CAR T cells are also endowed with an immune activating receptor. It is this dual-purpose function of antigen targeting and immune activation that gives CAR T cells their anti-cancer potency.
Whereas CAR T-cell therapy had been limited to inpatient treatment at university medical centers, patients who quality for the study can now receive therapy in the outpatient setting.
A Phase I study of JCAR017 in patients with aggressive forms of B-cell lymphoma found that it provided "a durable reduction or eradication of cancer," including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.
CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.
Providence Cancer Institute is one of 13 centers in the United States currently participating in this study. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614 or submit a referral form. Contact us early for consideration, before the patient receives a salvage therapy or stem cell transplant.
See more studies
New research studies are added frequently. See all studies in all cancer types currently open at Providence Cancer Institute.
Providence St. Joseph Health's Supportive Housing Program Addresses Basic Human Needs
Cancer survivor trains to crush cancer at 2019 Hood to Coast relay
When an oncology nurse completed treatment for her own cancer, she was determined to help others finish can...
Providence Mission Hospital Will Relocate Its Outpatient Physical Therapy Clinic From Forbes Road To The Hospital's Mission Viejo Campus
As of April 27, 2023, Providence Mission Hospital will relocate its outpatient physical therapy clinic from Forbes Road to the hospital's Mission Viejo campus, which is less than two miles away.
Providence Holy Cross NICU expansion spurred by $750,000 secured by U.S. Rep. Tony Cárdenas
Providence Saint John's Health Center to offer Aquablation therapy
Providence Saint John's Health Center is now equipped to offer Aquablation therapy, a state-of-the-art robotic procedure to treat men with enlarged prostates.
ION Robot Offers Hope for Lung Cancer Patients
ION Robot Offers Hope for Lung Cancer Patients. Brothers receive lifesaving diagnoses with advanced-tech tool.
10 Health Care Trends to Watch in 2023
Innovations that empower the human connection top the list of Providence's fifth-annual health care predictions.
Rep. Mike Thompson awards Providence $1.3 million to support permanent supportive housing
On Jan. 20, 2023, the congressman met with Providence caregivers at the site of the future housing project to celebrate and award the funding.
New scholarship fund created to help residents pursue a health care career
The scholarship— made possible by Queen of the Valley Foundation and Napa Valley Community Foundation—began accepting applications this month
Providence remembers Bill Schonely
EVUSHELD clinic helps give back some freedom during the pandemic
Providence caregivers give immunocompromised patients a chance of normalcy during the pandemic.
Providence Saint John's opens last phase of clinical trial of promising drug for aggressive brain cancer
One patient tells his inspiring story of recovery
Providence Holy Cross Medical Center among America's 50 Best Hospitals for the fourth straight year
Providence St. Vincent Medical Center named one of America's 50 best hospitals
For third year in a row, Providence St. Vincent Medical Center has received America's 50 Best Hospitals Award. This recognition places Providence among the top 1% of the country's hospital
Providence Little Company of Mary Medical Center Torrance named as only high-performing maternity care hospital in South Bay
Providence Little Company of Mary Medical Center Torrance was the only South Bay hospital to earn recognition from U.S. News & World Report for high performance in maternity care.
In a Matter of Minutes
At Providence Little Company of Mary, stroke care is excellent and expedient.
Providence Alaska offers course on faith community nursing
Join the Alaska Faith Community Resource Center at Providence this January for a course focused on faith community nursing.
Providence Mission Hospital Foundation Welcomes New Chief Philanthropy Officer
Providence Mission Hospital Foundation announces the appointment of Nicole Balsamo as chief philanthropy officer.
Advancing cardiac care: a glimpse into the present and the future
Attend a FREE live virtual lecture on cardiac care led by experts on February 23, 2023, at 5:30 p.m.
Notice: Providence EDs busy in Humboldt County, Please Use for Emergencies Only
Like hospitals across the country, Providence emergency departments in Humboldt County are extremely busy.
Arrive in the Morning, Back Home in Just Hours
When even standing for a few minutes became excruciating, Mark Beckman knew it was time for a hip replacement. So, he started researching hospital rankings, quality ratings and surgeons' reputations—a
New study opens for non-GCB DLBCL patients under age 70
A new clinical trial offered at Providence Cancer Institute to study the safety and effectiveness of two different treatments for people under age 70 with previously untreated non-GCB DLBCL.